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Available online 16 January 2017Objective. Resistance to standard chemotherapy poses a major clinical problem in the treatment of ovarian
cancer patients. Adult-type granulosa cell tumor (AGCT) is a unique ovarian cancer subtype for which efﬁcient
treatment options are lacking in advanced disease. To this end, systematic drug response and transcriptomics
proﬁling were performed to uncover new therapy options for AGCTs.
Methods. The responses of three primary and four recurrent AGCTs to 230 anticancer compounds were
screened in vitro using a systematic drug sensitivity and resistance testing (DSRT) platform, coupled with
mRNA sequencing. The responses of the AGCTs were compared with those of human granulosa luteal cells and
bone marrow mononuclear cells.
Results. Patient-derived AGCT cells showed selective sensitivity to the Src family tyrosine kinase inhibitor
dasatinib. A combination of either dasatinib or an mTOR-inhibitor everolimus with paclitaxel resulted in syner-
gistic inhibition of AGCT cell viability. The key kinase targets of dasatinib and members of the mTOR pathwayKeywords:
Granulosa cell tumor
Kinase inhibitors
Ovarian cancer
Screening strategiesd Gynecology, Helsinki University Hospital, PO Box 400, 00290 Helsinki, Finland.
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Table 1
Patient characteristics.
Features Prim1
Tumor type Primar
Primary tumor stage Ia
Age at tumor in study/years from diagnosis 62/0
Tumor site Right o
Tumor size (cm)a 21
Tumor subtype Diffuse
Prior adjuvant therapies No
Treatment of tumor in study Surgery
New recurrence/follow-up (months) No/37
Abbreviations BEC: bleomycin, etoposide, carboplatin.
a Tumor size measured as the longest diameter measur
b BEC 13 cycles in 2004–2005 and 2007 in total, epirub
622 U.-M. Haltia et al. / Gynecologic Oncology 144 (2017) 621–630were constantly expressed atmRNAand protein levels, indicatingmultikinase signal addictions in the AGCT cells.
Transcriptomic characterization of the tumors revealed no known oncogenicmutations, suggesting that the drug
sensitivity of AGCTs was rather conveyed by selective target expression.
Conclusions.We used a systematic functional approach to reveal novel treatment options for a unique gyne-
cological cancer. The selective synergy found between taxanes and dasatinib ormTOR inhibitorswarrants further
clinical investigations of these combinations in relapsed or aggressive AGCTs and demonstrate that high-
throughput drug screening and molecular proﬁling can provide an effective approach to uncover new therapy
options.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Adult-type granulosa cell tumor (AGCT) is a unique sex-cord derived
ovarian malignancy [1], characterized by a single nucleotide missense
mutation in transcription factor FOXL2 (c.402CNG; C134W) [2]. Thema-
jority of AGCTs are diagnosed at an early stage, with an indolent clinical
course [3]. However, up to 30% of the tumors recur [4,5], and 50–70% of
relapsed patientswill eventually die of disease-related complications [5,
6]. Radical surgery is the primary treatment of AGCT, but additional che-
motherapy is needed in advanced stages and recurrent disease. Since
the 1980s, AGCT has been treatedmainly with platinum-based (cisplat-
in or carboplatin) chemotherapeutics, mostly in combination with ei-
ther bleomycin and etoposide (BEP/BEC) or taxanes (principally
paclitaxel). The response rates to BEP treatment vary from 37 to 83%
in older studies [7,8], whereas more recent evaluation of a small cohort
of patients who were classiﬁed using RECIST criteria reported that the
response rate to BEP was only 22% [9,10]. The efﬁcacy of paclitaxel in
AGCT treatment is similar to that of BEP [8]. Thus, new treatments for
advanced AGCTs are urgently needed. The relative rarity of the tumor
type makes randomized clinical trials challenging and underlines the
need for preclinical approaches.
AGCTs are considered chromosomally stable, and apart from the
mutation in FOXL2, frequent mutations in common oncogenes or
tumor suppressor genes have not been identiﬁed [1]. The pathogenesis
of AGCTs is thought to be driven by transcriptional changes caused by
the mutated FOXL2, leading to misregulation of proliferation and apo-
ptosis [11,12]. There are, however, no therapeutic means to speciﬁcally
target FOXL2 402C-NG mutation-mediated alterations in AGCT.
In the present study, we used an established high-throughput drug
sensitivity and resistance testing (DSRT) [13–15], in combination with
molecular and genomic proﬁling, with the aim to uncover new thera-
peutic options for AGCTs. We identiﬁed potential AGCT-selective com-
pounds, veriﬁed the expression of their target proteins, and
performed RNA sequencing with variant analysis in the same AGCTPrim2 Prim3
y Primary Primary
Ia Ia
61/0 56/0
vary Right ovary Left ovary
5 5
Diffuse Trabecular
No No
only Surgery only Surgery on
No/28 No/15
ed upon operation, and if multiple tu
icin + carboplatin 6 cycles in 2009, lsamples. A combination of targeted agents, based on either dasatinib
or mTOR inhibitors combinedwith paclitaxel, resulted in synergistic in-
hibition of AGCT cell viability. As these targeted drugs are approved for
treating other malignancies, these results point to a straightforward
drug repurposing strategy for the treatment of inoperable or
chemoresistant AGCTs.2. Materials and methods
2.1. Primary AGCT cultures and GCT cell lines
The ethics committee of Helsinki University Central Hospital and the
National Supervisory Authority for Welfare and Health in Finland ap-
proved this study. Informed consent was obtained from the patients
(N=7)who donated fresh AGCT tissue for the study. The clinical char-
acteristics of the AGCT patients are presented in Table 1. All AGCTswere
positive for the FOXL2 402CNG mutation (Supplementary methods).
Short-term primary tumor cell cultures were established as described
[16] from three primary and four recurrent AGCTs during 2012–2015.
All primary cultured AGCT samples expressed known AGCT markers
(ERβ, FOXL2, GATA4, AMHRII and inhibin-α) (data not shown). The pri-
mary AGCT cells were cultured for 4–7 days to increase the cell number
in Dulbecco's modiﬁed Eagle's medium (DMEM)/Ham's F-12 medium,
supplemented with 10% FBS, penicillin/streptomycin, and L-glutamine
(Gibco, Grand Island, NY, USA) in a humidiﬁed environment at 37 °C
and 5% CO2. The cells were trypsinized, counted, and suspended in the
above-mentioned medium for high-throughput DSRT.
The KGN cell line [17] originating from a recurrent AGCT was con-
ﬁrmed to harbor the FOXL2 c.402CNG mutation and was used for both
DSRT and drug combination experiments. The COV434 cell line [18],
which originates from a juvenile GCT, was also used for DSRT and
drug combination experiments. COV434 does hot harbor the FOXL2mu-
tation and lacks also FOXL2 protein expression. Both cell lines were ob-
tained from the Riken BioResource Center. The KGN and COV434 cellsRec1 Rec2 Rec3 Rec 4
Recurrence
n:o I
Recurrence
n:o I
Recurrence
n:o V
Recurrence
n:o I
Ic Ia Ic Ic
66/27 82/9 60/25 66/12
Pelvis Pelvis Pelvis Pelvis
7 (3 tumors) 16 (2 tumors) 25 (4 tumors) 17
Diffuse Trabecular Diffuse Trabecular
No No Yesb No
ly Surgery and BEC × 4 Surgery only Surgery only Palliative treatment
Yes/12 Yes/3 Yes/15 –
mors, the diameters were summed.
etrozole 2,5 mg × 1 from 2011.
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with 10% FBS, penicillin/streptomycin, and L-glutamine (Gibco), and
passaged for b6 months following receipt or resuscitation of a frozen
cell vial that tested negative for mycoplasma infection.
2.2. Control cell models
As controls, three samples of pooled human granulosa-luteal (hGL)
cells obtained from women undergoing in vitro fertilization treatment
at the Department of Obstetrics and Gynecology, Helsinki University
Hospital were screened. hGL cells are mural benign granulosa cells
from hCG-primed preovulatory follicles. Each of the three hGL pools
consisted of granulosa-luteal cells derived from 78 to 122mature ovula-
tory follicles from four to seven different patients. The hGL cells were
isolated as previously described [19], and identiﬁed wild-type for the
FOXL2 402CNG mutation. Prior to the DSRT screen, freshly isolated
hGL cells were suspended in DMEM/F12 growthmedium, supplement-
ed with 2.5% Nu-serum I, ITS+™ Premix (both from BD Biosciences,Fig. 1. Drug sensitivity proﬁles of AGCT cells correlate with GCT cell lines and hGL cells. AGCT dr
(DSRT)were comparedwith the corresponding proﬁles of FOXL2 C134Wmutation positive GCT
hGL pools (C) in pair-wise scatterplots. Average DSS values for the seven AGCT samples and the
(DSS=5), whichwas used to ﬁlter out insensitive drugs (see Suppl. Fig. S1). Compoundswere
used for detecting differences in responses to compounds at a conservative signiﬁcance cut-o
exhibited signiﬁcantly different response proﬁles between AGCT and hGL: in addition to th
compounds showed differential responses: dasatinib, (+)JQ1, PF477736, obatoclax, linsitinib,Bedford, MA, USA), penicillin/streptomycin, and L-glutamine (Gibco).
As a second control cell model, DSRT data derived from bone marrow
mononuclear cells from seven healthy donors were used [14]. To iden-
tify AGCT-selective responses, AGCT cell responses were compared to
those from a collection of 68 cell lines derived from other solid tumors,
including breast [20], ovarian, lung, and pancreatic cancers.2.3. DSRT
DSRT was performed as previously described [14] on primary cul-
tured AGCT, hGL, bone marrow mononuclear, KGN, and COV434 cells
using a panel of 230 compounds (Supplementary Table S1). Twentymi-
croliters of a single cell suspension (1000 cells/well for the primary
AGCT cells and KGN and COV434 cell lines and 1000–2000 cells/well
for the hGL cells) were transferred to each predrugged well using a
MultiDrop Combi (Thermo Scientiﬁc, Waltham, MA, USA) peristaltic
dispenser. After 72 h of incubation, the cell viability was measuredug sensitivity score (DSS) proﬁles obtained from the drug sensitivity and resistance testing
cell line KGN (A), a FOXL2wild type GCT cell line COV434 (B), and FOXL2wild type healthy
three hGL pools were used in the comparisons. The dotted lines mark the response cut-off
grouped according to theirmechanisms of action (color coding). RankProduct analysiswas
ff level (FDR b 0.05), and these compounds are labeled. In panel 1C multiple compounds
e marked antimitotics, topoisomerase- and PI3K/mTOR –inhibitors, also the following
SNS-032, alvocidib, BMS-754807 and YM155.
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son, WI, USA) (see Supplementary methods for details).
2.4. Scoring and clustering of drug response proﬁles
To quantitatively proﬁle theDSRT-wide drug responses of individual
samples and to compare the drug responses between theAGCT samples,
the model-based drug sensitivity score (DSS) was calculated [13]. DSS
summarizes the area under the dose-response curve over the entire
dose range.
The differential drug responses of the AGCT cells were scored by cal-
culating the difference between the DSS of the patient sample and the
average DSS of either the hGL or bone marrow cells (selective DSS,
sDSS). The correlation analysis of drug screening data was performed
between AGCT and KGN/COV434/hGL cells with and without applying
a cutoff of 5 DSS units. Rank product analysis of differential drug re-
sponse was performed between AGCT and KGN/COV434/hGL cells
using the R-package “RankProd” at false discovery rate of 5%
(FDR b 0.05) [21]. Clustering of the drug sensitivity proﬁles across the
AGCT and control samples was performed using Ward's unsupervised
hierarchical clustering procedure with Euclidean and Manhattan dis-
tance measures for the drug and sample proﬁles, respectively, using
heatmap.2 function in “gplots” R package. The associations between
the DSS proﬁles were analyzed with Spearman's rank correlation coefﬁ-
cient using the R 3.1.0 statistical software platform (http://www.r-
project.org/).
2.5. Drug combination testing
KGN and COV434 cell viability was tested in response to the drug
combinations in a matrix format, with combinations of paclitaxel with
either dasatinib, everolimus, AZD8055, or PF-04691502 (the dosages
of each compound are provided in Supplementary Table S3). One thou-
sandKGNor COV434 cellswere plated perwell on predrugged 384-well
plates and incubated for 72 h. The cell viability was measured with
CellTiter-Glo. Drug combination synergy was quantiﬁed by comparing
the observed joint inhibition level at each dose combination to the ex-
pected combination effect using the zero interaction potency model
[22].
2.6. RNA sequencing and variant analysis
We performed RNA sequencing for ﬁve of the seven tested AGCT
samples. Two samples were not sequenced due to tissue RNA quality.
RNA-sequencing data on three unrelated hGL samples [23] were used
for gene expression proﬁling and variant analysis. RNA was extracted,
prepared and sequenced as described in the Supplementary methods.
RNA-sequencing reads were corrected for adapters and trimmed for
quality. Sequencing data were then mapped to human reference ge-
nome and assigned to genomic features. Transcript abundance was
measured as Fragments Per Kilobase of exon per Million fragments
mapped (FPKM) (for details, see Supplementarymethods). Variant call-
ing from RNA sequencing reads was performed on the AGCT samples
using Genome Analysis Toolkit (GATK) [24]. For details see Supplemen-
tary methods.
2.7. Human AGCT tissue microarray and immunohistochemistry
A previously characterized AGCT tissue microarray [25] containing
quadruple cores from 71 primary and 12 recurrent AGCTs was utilized
for immunohistochemical staining of the drug targets. All histologicalFig. 2. Dasatinib exhibits selective response against two control cell models. Average DSS values
and bone marrowmononuclear cells to obtain selective drug sensitivity scores (sDSS). Average
over 5.0 against hGL cell (A) and bone marrow mononuclear cell (C) control models. Heatma
between the individual responses of the seven AGCT samples against the hGL cell (B) and theAGCT diagnoses were histologically re-evaluated (R.B.) and tested pos-
itive for FOXL2 (c.402CNG; C134W). As controls, normal ovarian tissue
sections from two premenopausal women operated upon for cervical
cancer were used.
The AGCT tissue microarray, tissue sections from all the available
AGCT samples screened in this study (AGCT Prim 1, 2, and 3 and Rec 1
to 3), and control ovary sections were stained as previously described
[25], with the following primary antibodies and dilutions: anti-
survivin 1:400 (sc-10811, Santa Cruz Biotechnology Inc., CA, USA),
anti-mTOR 1:50 (#2983, Cell Signaling Technology Inc., MA, USA),
anti-AKT (#4691, Cell Signaling Technology Inc.) 1:2000, anti-c-Src
(sc-8056, Santa Cruz Biotechnology Inc.) 1:800, anti-PDGFRA 1:1200
(sc-338, Santa Cruz Biotechnology Inc.), anti-PDGFRB 1:2000 (sc-339,
Santa Cruz Biotechnology Inc.) and anti-EPHA5 1:1200 (sc-1014, Santa
Cruz Biotechnology Inc.). Immunostaining of granulosa cells in small an-
tral follicles was used as baseline (intermediate) staining to which the
staining of tumor samples was compared. AGCT immunostaining was
graded into high (including intermediate) or low (including negative)
groups based on the staining intensity. Two researchers (N.A. and U.-
M.H.) performed the evaluation independently, and disagreements
were resolved by a joint review.
3. Results
3.1. AGCTs exhibited consistent drug response proﬁles
A high-throughput DSRT platform [14] was used for screening the
responses of three primary and four recurrent AGCTs, as well as those
of GCT cell lines KGN and COV434 and hGL cells, to a panel of 230 com-
pounds (Supplementary Table S1). The drug response proﬁles were
quantiﬁed using the DSS [13] (Supplementary Table S2). Comparison
of the average AGCT response proﬁles showed a high correlation with
the KGN proﬁle (Spearman's correlation r = 0.83; Fig. 1A), whereas
the correlationwith the COV434 cell line and hGL referencewasweaker
(r= 0.74 and r= 0.68, respectively, Fig. 1B and C). To exclude the ef-
fects of datapoints near the origin, we also repeated this comparison
after ﬁltering out insensitive drugs (DSS b 5), which decreased the cor-
relations (Supplementary Fig. S1). The functional similarities between
the KGN cell line and AGCTs were further investigated by comparing
their gene expression proﬁles, showing similarly high correlations,
that also decreased when the non-expressed genes were ﬁltered out
(Supplementary Fig. S2). These results indicate that the KGN cell line
mimics the AGCT response proﬁle, thus providing a molecularly-
matched cell model that is more readily exploitable than primary cul-
tured AGCT cells.
3.2. Selective DSS analysis revealed potential therapeutic compounds for
AGCT
AGCT drug selectivity was ﬁrst evaluated against hGL cells. Among
the AGCT samples, 14 compounds exhibited a high selective response
(mean sDSS ≥5) (Fig. 2A, Supplementary Fig. S3). Of the targeted com-
pounds, the tyrosine kinase inhibitor dasatinib resulted in the highest
selective sensitivity in all the tumors (mean sDSS = 11.3). Three
AGCTs exhibited markedly higher selectivity for dasatinib: Prim 1,
Prim 3, and Rec 4 (sDSS of 15.0, 13.3, and 13.7, respectively). The
survivin inhibitor YM155, CHK1-inhibitor PF477736, and BCL-2/BCL-
XL-inhibitor obatoclax also showed relatively high selectivity (mean
sDSS of N5) (Fig. 2A, B, Supplementary Fig. S3). However, the other test-
ed BCL-2-inhibitors did not appear to have any selectivity for AGCT. Of
the traditional chemotherapeutic antimitotic drugs, docetaxel andof the seven AGCT samples were compared with the corresponding values of healthy hGL
sDSS values (+SEM) of the seven AGCTs were plotted for compounds with average sDSS
p plot of the sDSS proﬁles of the seven AGCT samples display similarities and differences
bone marrow mononuclear cell (D) controls.
626 U.-M. Haltia et al. / Gynecologic Oncology 144 (2017) 621–630paclitaxel were the most effective (mean sDSS of 15.2 and 10.9, respec-
tively). Six of the 14 selective compounds identiﬁed were antimitotic
microtubule-targeting agents. It is likely that antimitotics and topo-
isomerase II inhibitors were overrepresented as selective compounds
for AGCT due to the quiescent state of the hGL cells in vitro (Fig. 2B, Sup-
plementary Fig. S3).
The AGCT response proﬁle to bonemarrowmononuclear (BM) cells
was also compared to evaluate the drug sensitivity against healthy pro-
liferating cells. Dasatinib and YM155were both selective against the BM
reference model (mean sDSS of 10.2 and 18.1, respectively, Fig. 2C). In
total, 18 compounds exhibited high selectivity against the BM cells
(mean sDSS, ≥5), including several investigational compounds targeting
mTOR/PI3K (ﬁve compounds) and heat shock protein 90 (three com-
pounds) (Fig. 2D, Supplementary Fig. S4). Further, dasatinib and
YM155 exhibited selective efﬁcacy compared to a panel of 68 cancer
cell lines derived from solid breast, ovarian, lung, and pancreatic cancers
(Supplementary Fig. S5). Taken together, AGCTs showed selective sensi-
tivity to dasatinib, PI3K/mTOR inhibitors, taxane antimitotics, and the
survivin inhibitor YM155. Based on their clinical availability, the most
interesting new selective compounds are dasatinib, the rapamycin ana-
logmTOR inhibitors everolimus and temsirolimus, and the taxanes pac-
litaxel and docetaxel.
Of interest, both the FOXL2mutation-positive primary AGCT and KGN
cells were sensitive to the tyrosine kinase inhibitor dasatinib, whereas the
FOXL2 wild-type COV434 and hGL cells were resistant (Fig. 1). The re-
sponse patterns to the other tyrosine kinase inhibitors did not differ be-
tween the FOXL2mutation-positive and wild-type cells. Compared with
primaryAGCT cells, theGCT cell linesweremore sensitive to conventional
chemotherapeutics, such as antimitotic compounds, topoisomerase in-
hibitors, and tubulin stabilizers (Fig. 1). In addition, there were multiple
compounds earlier implicated as potential AGCT treatment that hadnoef-
fect on AGCT in our screen. Notably, hormone inhibitors had no effect on
AGCT cell viability, similar to EGFR-inhibitors. Further, inhibition of RAS-
RAF-MEK-ERK pathway showed only a minimal response in AGCT cells,
whereas the GCT cell lines showed moderate sensitivity to these inhibi-
tors (Supplementary Table S4).3.3. Dasatinib and mTOR/PI3K inhibitors synergistically inhibited AGCT cell
viability in combination with paclitaxelNext, the efﬁcacy of the selective targeted compounds dasatinib and
mTOR inhibitors everolimus, AZD8055, and PF-04691502were evaluat-
ed in dual combinations with the traditional chemotherapeutic pacli-
taxel in the two GCT cell lines KGN and COV434. The dual
combination of dasatinib with paclitaxel revealed synergy across the
dose range of 1–10 nM for dasatinib and 3–30 nM for paclitaxel in the
KGN cells but not in the FOXL2wild-type COV434 cells (Fig. 3A and E, re-
spectively). The highest synergy in KGN cells was reached with a
1–3 nM dose of dasatinib and 10 nM dose of paclitaxel. The combina-
tions of mTOR-inhibitors and paclitaxel also induced synergistic inhibi-
tion of KGN cell viability at relatively low concentrations. The highest
synergy in KGN cells was reached at doses of between 30 and 100 nM
and 1–3 nM for everolimus and paclitaxel, respectively (Fig. 3B),where-
as no synergy was detected in the COV434 cells at low drug concentra-
tions (Fig. 3F). The ATP-competitive mTOR kinase inhibitors PF-
04691502 and AZD8055 also showed synergy with paclitaxel at a
1–10 nM dose of each compound (Fig. 3C and D, respectively), whereas
the COV434 cells exhibited a negligent or low synergistic response (Fig.
3G and H, respectively).Fig. 3. Dual combinations with paclitaxel and novel targeted compounds synergistically inhibit
paclitaxel togetherwith either dasatinib, everolimus, PF-04691502 orAZD8055. The results are p
color and antagonismbygreen color. Synergistic inhibition of KGN cell viabilitywas foundat low
same doses (E). Combination treatment with paclitaxel and mTOR inhibitors also synergistical3.4. Selective drug sensitivity of AGCTs was conveyed by differential target
expression rather than somatic mutations
Five of the seven tested AGCT samples (Prim 1 and Rec 1–4) were
RNA-sequenced for gene expression analysis and mutation calling. Var-
iant analysis of the RNA-sequencing data did not reveal known cancer-
associated mutations in the samples tested. However, 108 potentially
oncogenic gene variants were detected with COSMIC ID, including a
frameshift insertion in ARF1 (ADP ribosylation factor-1) and stop-loss
codon in HLA-G (Supplemental Fig. S6). ARF1 and HLA-G variants were
present in four of ﬁve tumors (the mutation was absent in Rec 3 and
Rec 2, respectively). Mutation calling for dasatinib and PI3K/mTOR in-
hibitor target genes was conducted using the RNA-sequencing data.
Consistent with the lack of mutations in common cancer genes, neither
codon-changing nor protein-truncating variants was found in dasatinib
target genes or PI3K/mTOR pathway genes (Supplementary Fig. S6).
Dasatinib is a multitarget tyrosine kinase inhibitor targeting, for ex-
ample, ABL1, Src family kinases, KIT, PDGFR, and ephrin receptors. Com-
pared to hGL cells, the overall mRNA expression levels of several ephrin
receptors (especially EPHA5 and EPHB3), PDGFRA, PDGFR, and KIT, were
higher in the AGCTs (Fig. 4A). In addition, althoughmost of the Src fam-
ily members were abundantly expressed in AGCTs, only FYN expression
was notably higher in theAGCTs than in the hGL cells. Corroborating the
drug response proﬁles, genes encoding for the direct target proteins of
the most efﬁcient compounds were consistently expressed in the
AGCTs at themRNA level (Fig. 4A), andmanymembers of themTOR sig-
nalingpathwaywere also abundantly expressed in both AGCT and gran-
ulosa luteal cells (Fig. 4B).
Finally, the protein expression patterns of SRC, PDGFRA, PDGFRB,
and EPHA5, aswell as those ofmTOR and its downstreamsignalingmol-
ecule AKT and survivin,were assessed in the tested AGCT samples (Prim
1–3, Rec 1–3) and in an AGCT tissue microarray (Supplementary
Table S5, Supplementary Fig. S7). All these targets were abundantly
expressed at the protein level. However, there were no signiﬁcant dif-
ferences between primary and recurrent tumors, and the expression
levels were not correlated with patient survival (data not shown).
Taken together, these data suggest that the observed drug sensitivity
of AGCTs was conveyed by selective target expression rather than by
known oncogenic mutations.4. Discussion
In the present study, we systematically tested the drug sensitivity of
primary cultured AGCT cells and GCT cell lines utilizing a high-
throughput DSRT platform that comprised both traditional chemother-
apeutics and targeted compounds (both investigational and approved).
The results revealed novel targeted compounds that selectively de-
creased AGCT cell viability. Importantly, the study also revealed syner-
gistic growth inhibition between the targeted compounds, dasatinib,
and several mTOR-inhibitors, in combination with the current ﬁrst-
line treatment, paclitaxel.
The integration of data obtained from DSRT assays and molecular
proﬁling has previously been shown to be a powerful strategy to
identify individualized treatment options and potential biomarkers
in hematological malignancies and prostate cancer [13–15]. This ap-
proach was applied herein to primary ovarian cancer cells derived
from AGCT patients. To date, there are no established FOXL2
c.402CNGmutation-positive in vivomodels to test for drug responses
in AGCTs, further highlighting the importance of preclinical ap-
proaches to test new treatments for AGCT. DSRT is a promisingAGCT cell viability. GCT cell lines KGN and COV434 were treated with increasing doses of
resented as 2D contour plotwhere synergistic inhibition of cell viability is indicated by red
doses of paclitaxel and dasatinib (A),while no synergywasdetected inCOV434 cells at the
ly inhibited KGN cells (B-D) but not COV434 cell viability (F\\H) at low doses.
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Fig. 4.Dasatinib targets andmembers of PI3K/mTOR pathway are expressed in AGCTs. mRNA expression levels of the targets of dasatinib (A) and PI3K/mTOR inhibitors (B) were assessed
in ﬁve AGCT samples using the average ribo-depleted mRNA levels of samples. The average mRNA expression of 3 pooled hGL cell samples were used as control and FPKM values are
represented in log2 scale. Red bars implicate the AGCT samples and blue bars hGL samples. The bar plots present mean + SD.
628 U.-M. Haltia et al. / Gynecologic Oncology 144 (2017) 621–630functional approach to reveal novel treatment targets in this rare
tumor subtype, which exhibits only little genetic variation between
individual cases. Based on our study, responses of KGN cell line
were mostly convergent with those seen in AGCT cells. Since also
the gene expression levels were highly correlated between these
cells, KGN can be regarded as a useful cell model for AGCT. RNA se-
quencing and subsequent mutation calling conﬁrmed the lack of mu-
tations in known oncogenes in the AGCT patients, indicating that
drug sensitivity was mainly conveyed by selective target expression.
Even though our sample size was limited, we think these results are
representative for AGCT, considering the similarity of transcriptomic
proﬁles among the individual tumors. Of the detected variants ARF1
is a GTP-binding molecule, known to have an essential role in phos-
phorylation of SRC [26]whereas HLA-G plays a role in tumor immune
surveillance [27]. As the variant types for ARF1 and HLA-G were
frameshift insertion and stoploss type respectively, they are expect-
ed to affect the protein function. However the clinical signiﬁcance of
these variants detected herein in a subset of AGCTs will require fur-
ther study.
Dasatinib is a tyrosine kinase inhibitor that is widely used in the
treatment of chronic myeloid leukemia [28], showing efﬁcacy also
against solid tumors when used in combination with other drugs
[29,30]. Although dasatinib primarily targets SRC and ABL, it also in-
hibits a variety of other tyrosine kinases, such as PDGFR and ephrin
receptors [31]. Consistent with an earlier report of the effects of an
SRC inhibitor in KGN cells [32], the present study showed that
dasatinib strongly and selectively inhibited AGCT cell viability. Inter-
estingly, dasatinib was effective in FOXL2-mutation positive AGCTs
and the KGN cell line, whereas the responses in FOXL2 wild-type
COV434 cells and hGL reference cells were signiﬁcantly weaker.
Moreover, the synergistic effects were selective to AGCTs, as the syn-
ergy between dasatinib and paclitaxel was evident in KGN cells,whereas no synergy was seen in the FOXL2 wild-type COV434 cells.
However, this possible association between the dasatinib response
and FOXL2 mutation will need to be further validated in functional
studies. Given that the other KIT or PDGFR inhibitors in the studied
drug collection did not show a selective response, the cell viability
inhibiting effect of dasatinib is likely to be conveyed through speciﬁc
ephrin receptors or Src family kinases. Consistently, most of the
dasatinib targets were highly expressed at the mRNA level and also
showed strong expression in the majority of AGCTs at the protein
level. The present study found no mutations in the dasatinib target
genes, and further studies are required to conﬁrm the role of both
ephrin receptors and Src family kinases in AGCTs.
The PI3K/Akt/mTOR signaling pathway regulates cell growth and
proliferation, and activation of mTOR and Akt has been shown to
promote granulosa cell proliferation and differentiation [33]. This
signaling pathway is also active in AGCT [34], and treatment with
the mTOR inhibitor everolimus has been shown to reduce tumor
growth in a mouse GCT model [35]. mTOR inhibitors selectively
inhibited AGCT cell viability in our systematic screen, and many
key components of the mTOR pathway were abundantly expressed
in AGCTs at the mRNA level. In addition, highly expressed survivin
has been shown to be regulated by the mTOR pathway [36]. Survivin
is also one of the downstream effectors of the beta-catenin pathway,
which promotes malignant tumorigenesis in granulosa cells [37]. Al-
though the survivin inhibitor YM155 has shown promising results in
preclinical models, the clinical efﬁcacy of YM155 is limited, and its
drug development has recently been discontinued. However, in a
recent study with ovarian cancer patients, survivin was used as an
antigen to generate cancer-speciﬁc vaccine-induced immune
responses [38]. Altogether, these ﬁndings implicate a potential role
for mTOR inhibitors in the treatment of AGCTs and support the
potential of survivin as a therapeutic target.
629U.-M. Haltia et al. / Gynecologic Oncology 144 (2017) 621–630In accordance with clinical experience, paclitaxel and docetaxel
were the most efﬁcient traditional chemotherapeutics for AGCTs.
Importantly, the present study revealed signiﬁcant synergy between
paclitaxel and dasatinib and between paclitaxel and mTOR inhibi-
tors. In epithelial ovarian cancer cells, dasatinib has been shown to
enhance the antitumor activities of paclitaxel and carboplatin, and
this combination has also been tested in a phase I trial, with evidence
of clinical activity [30,39]. Synergy between mTOR inhibitors and
paclitaxel has also been reported in breast cancer cells [40]. The
lack of chromosomal instability and low intra- and intertumoral
heterogeneity in AGCTs may render these cancers sensitive to such
synergistic treatments in the clinical setting.
In conclusion, the present study introduced a systematic drug
screening approach in ovarian cancer cells to reveal novel potential
compounds and drug combinations, which can be further tested in clin-
ical trials. Molecular proﬁling revealed a relatively homogenous set of
AGCT tumors, in which the drug sensitivities were conveyed by their
target gene expressions. The selective response of dasatinib in all tested
AGCTs highlights dasatinib as the most potential drug for AGCTs in our
screen. The combination of dasatinib and paclitaxel has been shown to
bewell tolerated in clinical trials of other tumor types [30]. Importantly,
the herein observed synergy of dasatinib and paclitaxel urges clinical
testing of this combination in relapsed or aggressive AGCTs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2016.12.016.
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